{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:05:33Z","timestamp":1793372733595,"version":"4.5.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Bedrocan International B.V."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cannabis Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Despite the Netherlands having one of the world\u2019s oldest medical cannabis programs, the majority of people who use cannabis for medicinal purposes continue to rely on non-prescribed sources. This study investigates patterns of use, motives for use, perceived effectiveness, and barriers to accessing prescribed cannabis among individuals self-medicating with non-prescribed cannabis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A cross-sectional online survey was conducted between January and April 2023, using convenience sampling primarily via social media. Participants (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u20091059) were adults (18 years or older) residing in the Netherlands who self-reported current use of non-prescribed cannabis-based products to manage physical or mental health symptoms.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Cannabis was used to manage a wide range of conditions, most commonly chronic pain, sleep disorders, depression, and ADHD\/ADD, with three out of four participants reporting use for multiple conditions. Most participants obtained cannabis from coffeeshops, although one in four also reported home cultivation as a source. Participants typically smoked cannabis with tobacco, reported (near-)daily use for therapeutic purposes, and indicated a monthly expenditure of \u20ac100. The majority was not aware of the THC and CBD content of their products. Perceived effectiveness was rated as high, and more than half of those with a history of prescription medication use reported substituting cannabis for these medications. Only a minority of participants had ever used, or were currently using, prescribed cannabis. Commonly cited barriers included perceived lower quality, higher cost, and lower ease of access compared with non-prescribed cannabis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The widespread use of non-prescribed cannabis for medicinal purposes in the Netherlands reflects both unmet health needs and barriers within the regulated medical cannabis system. Risky use practices \u2013 such as smoking cannabis with tobacco and using products without knowing their cannabinoid content \u2013 raise public health concerns. The findings highlight the need for harm reduction strategies and policies that better align medical cannabis regulation with patients\u2019 real-world behaviours and care needs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s42238-025-00355-y","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T17:16:29Z","timestamp":1764695789000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Medicinal use of non-prescribed cannabis: a cross-sectional survey on patterns of use, motives for use, and treatment access in the Netherlands"],"prefix":"10.1186","volume":"8","author":[{"given":"Lisa","family":"Strada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Korteling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Vergeer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Oomen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"key":"355_CR1","unstructured":"Instituut Verantwoord Medicijngebruik & Bureau voor Medicinale Cannabis. Medicinale cannabis informatiebrochure voor artsen en apothekers. Den Haag: Ministerie van VWS en Instituut Verantwoord Medicijngebruik; 2021."},{"key":"355_CR2","unstructured":"Government of the Netherlands. Controlled Cannabis Supply Chain Experiment. Background information and experiment design [Internet]. [cited 2025 Apr 22]. Available from: https:\/\/www.government.nl\/topics\/controlled-cannabis-supply-chain-experiment\/background-information-and-experiment-design"},{"key":"355_CR3","volume-title":"Al. E. Nationale drug monitor: Jaarbericht 2021","author":"MW Van Laar","year":"2021","unstructured":"Van Laar MW, Van Beek RJJ, Beenakkers EMT, Cruts AAN, Kuin MC, Meijer RF. Al. E. Nationale drug monitor: Jaarbericht 2021. Utrecht: Trimbos-instituut\/WODC; 2021."},{"key":"355_CR4","first-page":"31","volume":"159","author":"Stichting Farmaceutische Kengetallen","year":"2024","unstructured":"Stichting Farmaceutische Kengetallen. Kosten cannabino\u00efden gestegen met 9%. Pharmaceutisch Weekbl. 2024;159:31\u20132.","journal-title":"Pharmaceutisch Weekbl"},{"key":"355_CR5","volume-title":"THC-concentraties in wiet, Nederwiet En Hasj in nederlandse coffeeshops (2022\u20132023)","author":"P Oomen","year":"2024","unstructured":"Oomen P, Rigter S. THC-concentraties in wiet, nederwiet en hasj in Nederlandse coffeeshops (2022\u20132023). Utrecht: Trimbos Instituut; 2024."},{"issue":"11","key":"355_CR6","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1111\/bcp.13695","volume":"84","author":"L Dryburgh","year":"2018","unstructured":"Dryburgh L, Bolan N, Grof C, Galettis P, Schneider J, Lucas C, Martin J. Cannabis contaminants: sources, distribution, human toxicity and pharmacologic effects. Br J Clin Pharmacol. 2018;84(11):2468\u201376.","journal-title":"Br J Clin Pharmacol"},{"key":"355_CR7","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.forsciint.2019.02.049","volume":"298","author":"M P\u00e9rez-Moreno","year":"2019","unstructured":"P\u00e9rez-Moreno M, P\u00e9rez-Lloret P, Gonz\u00e1lez-Soriano J, Santos-\u00c1lvarez I. Cannabis resin in the region of Madrid: adulteration and contamination. Forensic Sci Int. 2019;298:34\u20138.","journal-title":"Forensic Sci Int"},{"key":"355_CR8","doi-asserted-by":"publisher","first-page":"571832","DOI":"10.3389\/fphar.2020.571832","volume":"11","author":"Z Montoya","year":"2020","unstructured":"Montoya Z, Conroy M, Vanden Heuvel BD, Pauli CS, Park SH. Cannabis contaminants limit pharmacological use of cannabidiol. Front Pharmacol. 2020;11:571832.","journal-title":"Front Pharmacol"},{"key":"355_CR9","unstructured":"Oomen P, Andree R, Rigter S, van Laar M. Onderzoek experiment gesloten coffeeshopketen - Rapportage nulmeting contaminantenanalyse [Internet]. Utrecht: Trimbos-instituut\/WODC; 2024. Available from: https:\/\/repository.wodc.nl\/bitstream\/handle\/20.500.12832\/3427\/3082G-experiment-gesloten-coffeeshopketen-nulmeting-contaminantenanalyse-volledige-tekst.pdf?sequence=1&isAllowed=y"},{"key":"355_CR10","unstructured":"Independer. Cannabis: geen vergoeding meer in 2018 [Internet]. 2017 [cited 2024 Oct 14]. Available from: https:\/\/weblog.independer.nl\/zorgverzekeringen\/cannabis-geen-vergoeding-meer-2018\/"},{"key":"355_CR11","unstructured":"Bijwerkingencentrum\u00a0&\u00a0Lareb. Bureau medicinale cannabis. Cohort studie Naar indicatie, pati\u00ebntenervaring En Veiligheid Van Het Gebruik Van medicinale cannabis in Nederland. \u2018S-Hertogenbosch: CIBG Ministerie van Volksgezondheid, Welzijn en Sport; 2023."},{"key":"355_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12954-020-00377-0","volume":"17","author":"N Lintzeris","year":"2020","unstructured":"Lintzeris N, Mills L, Suraev A, Bravo M, Arkell T, Arnold JC, Benson MJ, McGregor IS. Medical cannabis use in the Australian community following introduction of legal access: the 2018\u20132019 online Cross-Sectional cannabis as medicine survey (CAMS-18). Harm Reduct J. 2020;17:1\u20132.","journal-title":"Harm Reduct J"},{"key":"355_CR13","doi-asserted-by":"publisher","first-page":"e57595","DOI":"10.2196\/57595","volume":"10","author":"S Erridge","year":"2024","unstructured":"Erridge S, Troup L, Sodergren MH. Illicit cannabis use to self-treat chronic health conditions in the united kingdom: Cross-Sectional study. JMIR Public Health Surveillance. 2024;10:e57595.","journal-title":"JMIR Public Health Surveillance"},{"key":"355_CR14","volume-title":"Dunkelfeldanalyse Zur medizinischen versorgung Mit cannabisprodukten in Frankfurt. Modul des konzeptes \u201eMedizinisches cannabis in Frankfurt am Main. Endbericht","author":"B Werse","year":"2020","unstructured":"Werse B, Kamphausen G, Klaus L. Dunkelfeldanalyse zur medizinischen versorgung mit cannabisprodukten in Frankfurt. Modul des konzeptes \u201eMedizinisches cannabis in Frankfurt am Main. Endbericht. Frankfurt: Centre for drug research; 2020."},{"key":"355_CR15","volume-title":"Self-reported medicinal cannabis use in flanders: a study of user profiles and patterns of use. [Ghent","author":"F Bawin","year":"2020","unstructured":"Bawin F. Self-reported medicinal cannabis use in flanders: a study of user profiles and patterns of use. [Ghent. Belgium]: Ghent University. Faculty of Law and Criminology; 2020."},{"issue":"1","key":"355_CR16","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000489287","volume":"1","author":"A Hazekamp","year":"2018","unstructured":"Hazekamp A. The trouble with CBD oil. Med cannabis cannabinoids. 2018;1(1):65\u201372.","journal-title":"Med Cannabis Cannabinoids"},{"key":"355_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12954-021-00520-5","volume":"18","author":"SL Kvamme","year":"2021","unstructured":"Kvamme SL, Pedersen MM, R\u00f8mer Thomsen K, Thylstrup B. Exploring the use of cannabis as a substitute for prescription drugs in a convenience sample. Harm Reduct J. 2021;18:1\u20138.","journal-title":"Harm Reduct J"},{"issue":"1","key":"355_CR18","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1089\/can.2016.0007","volume":"1","author":"M Sexton","year":"2016","unstructured":"Sexton M, Cuttler C, Finnell JS, Mischley LK. A cross-sectional survey of medical cannabis users: patterns of use and perceived efficacy. Cannabis Cannabinoid Res. 2016;1(1):131\u20138.","journal-title":"Cannabis Cannabinoid Res"},{"issue":"3","key":"355_CR19","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.drugpo.2014.07.005","volume":"26","author":"P Hakkarainen","year":"2015","unstructured":"Hakkarainen P, Frank VA, Barratt MJ, Dahl HV, Decorte T, Karjalainen K, Lenton S, Potter G, Werse B. Growing medicine: small-scale cannabis cultivation for medical purposes in six different countries. Int J Drug Policy. 2015;26(3):250\u20136.","journal-title":"Int J Drug Policy"},{"key":"355_CR20","doi-asserted-by":"publisher","first-page":"885655","DOI":"10.3389\/fphar.2022.885655","volume":"13","author":"SL MacPhail","year":"2022","unstructured":"MacPhail SL, Bedoya-P\u00e9rez MA, Cohen R, Kotsirilos V, McGregor IS, Cairns EA. Medicinal cannabis prescribing in australia: an analysis of trends over the first five years. Front Pharmacol. 2022;13:885655.","journal-title":"Front Pharmacol"},{"key":"355_CR21","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.copsyc.2019.04.002","volume":"30","author":"TR Spindle","year":"2019","unstructured":"Spindle TR, Bonn-Miller MO, Vandrey R. Changing landscape of cannabis: novel products, formulations, and methods of administration. Curr Opin Psychol. 2019;30:98\u2013102.","journal-title":"Curr Opin Psychol"},{"key":"355_CR22","unstructured":"Nationale Drug Monitor. Cannabis 3.2.3 Gebruikspatronen en wijze van verkrijgen [Internet]. Trimbos-instituut, Utrecht & WODC. Den Haag; 2024 [cited 2024 Sep 16]. Available from: https:\/\/www.nationaledrugmonitor.nl\/cannabis-gebruikspatronen-en-wijze-van-v"},{"key":"355_CR23","doi-asserted-by":"crossref","unstructured":"Fortin D, Leroy V, Carrieri P, Matias J, Barr\u00e9 T. Relationships between motives for cannabis and cannabidiol use in people who co-use: results from the\u00a0European Web Survey on Drugs. Drug Alcohol Rev. 2025;44(6):1666\u201379.","DOI":"10.1111\/dar.14090"},{"key":"355_CR24","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.drugpo.2017.11.008","volume":"52","author":"C Russell","year":"2018","unstructured":"Russell C, Rueda S, Room R, Tyndall M, Fischer B. Routes of administration for cannabis use\u2013basic prevalence and related health outcomes: A scoping review and synthesis. Int J Drug Policy. 2018;52:87\u201396.","journal-title":"Int J Drug Policy"},{"key":"355_CR25","first-page":"13","volume":"158","author":"Stichting Farmaceutische Kerngetallen","year":"2023","unstructured":"Stichting Farmaceutische Kerngetallen. lichte daling verstrekkingen van medicinale cannabis. Pharmaceutisch Weekbl. 2023;158:13.","journal-title":"Pharmaceutisch Weekbl"},{"issue":"5","key":"355_CR26","doi-asserted-by":"publisher","first-page":"152","DOI":"10.18773\/austprescr.2020.052","volume":"43","author":"JC Arnold","year":"2020","unstructured":"Arnold JC, Nation T, McGregor IS. Prescribing medicinal cannabis. Australian Prescriber. 2020;43(5):152.","journal-title":"Australian Prescriber"},{"issue":"3","key":"355_CR27","doi-asserted-by":"publisher","first-page":"e0271079","DOI":"10.1371\/journal.pone.0271079","volume":"18","author":"M Shim","year":"2023","unstructured":"Shim M, Nguyen H, Grootendorst P. Lessons from 20 years of medical cannabis use in Canada. PLoS ONE. 2023;18(3):e0271079.","journal-title":"PLoS ONE"},{"issue":"6","key":"355_CR28","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1089\/can.2021.0164","volume":"7","author":"SA Pruyn","year":"2022","unstructured":"Pruyn SA, Wang Q, Wu CG, Taylor CL. Quality standards in state programs permitting cannabis for medical uses. Cannabis Cannabinoid Res. 2022;7(6):728\u201335.","journal-title":"Cannabis Cannabinoid Res"},{"issue":"1","key":"355_CR29","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s42238-022-00135-y","volume":"4","author":"A Asselin","year":"2022","unstructured":"Asselin A, Lamarre OB, Chamberland R, McNeil SJ, Demers E, Zongo A. A description of self-medication with cannabis among adults with legal access to cannabis in Quebec, Canada. J Cannabis Res. 2022;4(1):26.","journal-title":"J Cannabis Res"},{"key":"355_CR30","doi-asserted-by":"publisher","first-page":"101282","DOI":"10.1016\/j.smrv.2020.101282","volume":"51","author":"RC Cox","year":"2020","unstructured":"Cox RC, Olatunji BO. Sleep in the anxiety-related disorders: A meta-analysis of subjective and objective research. Sleep Med Rev. 2020;51:101282.","journal-title":"Sleep Med Rev"},{"issue":"1","key":"355_CR31","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41398-023-02622-z","volume":"13","author":"OS Hamilton","year":"2023","unstructured":"Hamilton OS, Steptoe A, Ajnakina O. Polygenic predisposition, sleep duration, and depression: evidence from a prospective population-based cohort. Translational Psychiatry. 2023;13(1):323.","journal-title":"Translational Psychiatry"},{"issue":"6","key":"355_CR32","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/papr.13220","volume":"23","author":"PM Mullins","year":"2023","unstructured":"Mullins PM, Yong RJ, Bhattacharyya N. Associations between chronic pain, anxiety, and depression among adults in the united States. Pain practice: Official J World Inst Pain. 2023;23(6):589\u201394.","journal-title":"Pain Practice: Official J World Inst Pain"},{"issue":"2","key":"355_CR33","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00406-024-01880-2","volume":"275","author":"E Hoch","year":"2025","unstructured":"Hoch E, Volkow ND, Friemel CM, Lorenzetti V, Freeman TP, Hall W. Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits. Eur Arch Psychiatry Clin Neurosci. 2025;275(2):281\u201392.","journal-title":"Eur Arch Psychiatry Clin Neurosci."},{"key":"355_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-072348","author":"M Solmi","year":"2023","unstructured":"Solmi M, De Toffol M, Kim JY, Choi MJ, Stubbs B, Thompson T, et al. Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies. BMJ. 2023. https:\/\/doi.org\/10.1136\/bmj-2022-072348.","journal-title":"BMJ"},{"issue":"1","key":"355_CR35","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00406-018-0970-7","volume":"269","author":"DJ Lowe","year":"2019","unstructured":"Lowe DJ, Sasiadek JD, Coles AS, George TP. Cannabis and mental illness: a review. Eur Arch Psychiatry Clin NeuroSci. 2019;269(1):107\u201320.","journal-title":"Eur Arch Psychiatry Clin NeuroSci"},{"issue":"6","key":"355_CR36","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1089\/can.2020.0120","volume":"7","author":"M Kalaba","year":"2022","unstructured":"Kalaba M, Ware MA. Cannabinoid profiles in medical cannabis users: effects of age, gender, symptoms, and duration of use. Cannabis Cannabinoid Res. 2022;7(6):840\u201351.","journal-title":"Cannabis Cannabinoid Res"},{"issue":"5","key":"355_CR37","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1080\/10826084.2022.2034872","volume":"57","author":"J Rup","year":"2022","unstructured":"Rup J, Freeman TP, Perlman C, Hammond D. Cannabis and mental health: adverse outcomes and self-reported impact of cannabis use by mental health status. Subst Use Misuse. 2022;57(5):719\u201329.","journal-title":"Subst Use Misuse"},{"key":"355_CR38","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00406-019-00984-4","volume":"269","author":"E Hoch","year":"2019","unstructured":"Hoch E, Niemann D, von Keller R, Schneider M, Friemel CM, Preuss UW, Hasan A, Pogarell O. How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review. Eur Arch Psychiatry Clin NeuroSci. 2019;269:87\u2013105.","journal-title":"Eur Arch Psychiatry Clin NeuroSci"},{"issue":"4","key":"355_CR39","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1037\/pro0000345","volume":"51","author":"D Feingold","year":"2020","unstructured":"Feingold D. Working with clients who self-medicate using cannabis: Mind the gap in knowledge. Prof Psychology: Res Pract. 2020;51(4):313\u20136.","journal-title":"Prof Psychology: Res Pract"},{"key":"355_CR40","doi-asserted-by":"publisher","first-page":"916","DOI":"10.3389\/fphar.2018.00916","volume":"9","author":"SS Stith","year":"2018","unstructured":"Stith SS, Vigil JM, Brockelman F, Keeling K, Hall B. Patient-reported symptom relief following medical cannabis consumption. Front Pharmacol. 2018;9:916.","journal-title":"Front Pharmacol"},{"issue":"4","key":"355_CR41","first-page":"109","volume":"73","author":"CW Webb","year":"2014","unstructured":"Webb CW, Webb SM. Therapeutic benefits of cannabis: a patient survey. Hawai\u2019i J Med Public Health. 2014;73(4):109.","journal-title":"Hawai\u2019i J Med Public Health"},{"issue":"1","key":"355_CR42","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1080\/02791072.2023.2285843","volume":"57","author":"D Fortin","year":"2025","unstructured":"Fortin D, Di Beo V, Carrieri P, Barr\u00e9 T. Therapeutic use and other reasons to consume cannabidiol: insight from the French and Italian contexts. J Psychoactive Drugs. 2025;57(1):110\u201320.","journal-title":"J Psychoactive Drugs"},{"issue":"1","key":"355_CR43","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s42238-023-00207-7","volume":"5","author":"J Jylkk\u00e4","year":"2023","unstructured":"Jylkk\u00e4 J, Hupli A, Nikolaeva A, Alanen S, Back AE, Lindqvist S, Krabbe A, Lavie-Ajayi M, Kantonen O. The holistic effects of medical cannabis compared to opioids on pain experience in Finnish patients with chronic pain. J Cannabis Res. 2023;5(1):38.","journal-title":"J Cannabis Res"},{"key":"355_CR44","unstructured":"National Academies of Sciences Engineering and Medicine. The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research. Washington (DC); 2017."},{"issue":"1","key":"355_CR45","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1089\/can.2019.0010","volume":"4","author":"D Piomelli","year":"2019","unstructured":"Piomelli D, Solomon R, Abrams D, Balla A, Grant I, Marcotte T, Yoder J. Regulatory barriers to research on cannabis and cannabinoids: A proposed path forward. Cannabis Cannabinoid Res. 2019;4(1):21\u201332.","journal-title":"Cannabis Cannabinoid Res"},{"key":"355_CR46","doi-asserted-by":"publisher","first-page":"110","DOI":"10.54695\/jges.202.0110","volume":"2020","author":"D Fortin","year":"2020","unstructured":"Fortin D, Massin S. Medical cannabis: thinking out of the box of the healthcare system. J De Gestion Et D \u00e9conomie m\u00e9dicales. 2020;2020:110\u20138.","journal-title":"J De Gestion Et D \u00e9conomie m\u00e9dicales"},{"key":"355_CR47","doi-asserted-by":"publisher","first-page":"1027159","DOI":"10.3389\/fpsyt.2022.1027159","volume":"13","author":"AK Schlag","year":"2022","unstructured":"Schlag AK, Zafar RR, Lynskey MT, Phillips LD, Nutt DJ. The value of real world evidence: the case of medical cannabis. Front Psychiatry. 2022;13:1027159.","journal-title":"Front Psychiatry"},{"key":"355_CR48","doi-asserted-by":"publisher","first-page":"904291","DOI":"10.3389\/fpubh.2022.904291","volume":"10","author":"D Fortin","year":"2022","unstructured":"Fortin D, Marcellin F, Carrieri P, Mancini J, Barr\u00e9 T. Medical cannabis: toward a new policy and health model for an ancient medicine. Front Public Health. 2022;10:904291.","journal-title":"Front Public Health"},{"issue":"2","key":"355_CR49","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1177\/00914509211070741","volume":"49","author":"SL Kvamme","year":"2022","unstructured":"Kvamme SL. With medicine in mind? Exploring the relevance of having recreational experience when becoming a medicinal cannabis user. Contemp Drug Probl. 2022;49(2):192\u2013212.","journal-title":"Contemp Drug Probl"},{"issue":"4","key":"355_CR50","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1080\/15265161.2019.1567193","volume":"19","author":"D Casarett","year":"2019","unstructured":"Casarett D, Abrams DI. Why insurance companies should pay for medical cannabis. Am J Bioeth. 2019;19(4):8\u201310.","journal-title":"Am J Bioeth"},{"issue":"03","key":"355_CR51","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1055\/a-2261-2269","volume":"57","author":"N Szejko","year":"2024","unstructured":"Szejko N, Becher E, Heimann F, Grotenhermen F, M\u00fcller-Vahl KR. Medicinal use of different cannabis strains: results from a large prospective survey in Germany. Pharmacopsychiatry. 2024;57(03):133\u201340.","journal-title":"Pharmacopsychiatry"},{"key":"355_CR52","unstructured":"Norman H. Czech Republic Doctors Prescribed 210 Kilograms Of Medical Cannabis In 2023 [Internet]. International Cannabis Business Conference; 2024 [cited 2024 Oct 14]. Available from: https:\/\/internationalcbc.com\/czech-republic-doctors-prescribed-210-kilo"},{"issue":"10","key":"355_CR53","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1016\/j.jval.2021.04.1276","volume":"24","author":"D Erku","year":"2021","unstructured":"Erku D, Shrestha S, Scuffham P. Cost-effectiveness of medicinal cannabis for management of refractory symptoms associated with chronic conditions: A systematic review of economic evaluations. Value Health. 2021;24(10):1520\u201330.","journal-title":"Value Health"},{"key":"355_CR54","doi-asserted-by":"publisher","first-page":"117954412110024","DOI":"10.1177\/11795441211002492","volume":"14","author":"C Vannabouathong","year":"2021","unstructured":"Vannabouathong C, Zhu M, Chang Y, Bhandari M. Can medical cannabis therapies be cost-effective in the non-surgical management of chronic knee pain? Clinical medicine insights. Arthritis Musculoskelet Disorders. 2021;14:11795441211002492.","journal-title":"Arthritis Musculoskelet Disorders"},{"issue":"4","key":"355_CR55","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s40261-025-01424-z","volume":"45","author":"ML Doucette","year":"2025","unstructured":"Doucette ML, Hemraj D, Macfarlan DL, Chin J, Fisher E. The cost effectiveness of adjunctive medical cannabis therapy in the treatment of moderate post-traumatic stress disorder. Clin Drug Investig. 2025;45(4):207\u201320.","journal-title":"Clin Drug Investig"},{"issue":"3","key":"355_CR56","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1089\/can.2024.0120","volume":"10","author":"HM Jeddi","year":"2025","unstructured":"Jeddi HM, Busse JW, Sadeghirad B, Levine M, MacCallum C, Wang L, Couban RJ, Tarride JE. Cost-effectiveness of medical cannabis versus opioids for chronic noncancer pain. Cannabis Cannabinoid Res. 2025;10(3):467\u201379.","journal-title":"Cannabis Cannabinoid Res"},{"issue":"5","key":"355_CR57","doi-asserted-by":"publisher","first-page":"211","DOI":"10.5694\/mja17.01247","volume":"209","author":"N Lintzeris","year":"2018","unstructured":"Lintzeris N, Driels J, Elias N, Arnold JC, McGregor IS, Allsop DJ. Medicinal cannabis in Australia, 2016: the cannabis as medicine survey (CAMS-16). Med J Aust. 2018;209(5):211\u20136.","journal-title":"Med J Aust"},{"issue":"5","key":"355_CR58","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1177\/0269881117699616","volume":"31","author":"BJ Piper","year":"2017","unstructured":"Piper BJ, DeKeuster RM, Beals ML, Cobb CM, Burchman CA, Perkinson L, Lynn ST, Nichols SD, Abess AT. Substitution of medical cannabis for pharmaceutical agents for pain, anxiety, and sleep. J Psychopharmacol. 2017;31(5):569\u201375.","journal-title":"J Psychopharmacol"},{"key":"355_CR59","doi-asserted-by":"publisher","first-page":"102675","DOI":"10.1016\/j.ctim.2021.102675","volume":"58","author":"Y Zolotov","year":"2021","unstructured":"Zolotov Y, Metri S, Calabria E, Kogan M. Medical cannabis education among healthcare trainees: A scoping review. Complement Ther Med. 2021;58:102675.","journal-title":"Complement Ther Med"},{"key":"355_CR60","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.drugpo.2018.03.025","volume":"57","author":"Y Zolotov","year":"2018","unstructured":"Zolotov Y, Vulfsons S, Zarhin D, Sznitman S. Medical cannabis: an oxymoron? Physicians\u2019 perceptions of medical cannabis. Int J Drug Policy. 2018;57:4\u201310.","journal-title":"Int J Drug Policy"},{"key":"355_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12875-021-01559-w","volume":"22","author":"S R\u00f8nne","year":"2021","unstructured":"R\u00f8nne S, Rosenb\u00e6k F, Pedersen LB, Waldorff FB, Nielsen JB, Riisgaard H, S\u00f8ndergaard J. Physicians\u2019 experiences, attitudes, and beliefs towards medical cannabis: a systematic literature review. BMC Fam Pract. 2021;22:1\u201321.","journal-title":"BMC Fam Pract"},{"issue":"1","key":"355_CR62","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1177\/1049909115604669","volume":"34","author":"BH Carlini","year":"2017","unstructured":"Carlini BH, Garrett SB, Carter GT. Medicinal cannabis: a survey among health care providers in Washington state. Am J Hospice Palliat Med. 2017;34(1):85\u201391.","journal-title":"Am J Hospice Palliat Med"},{"key":"355_CR63","unstructured":"MedBud. Navigating Medical Cannabis in the UK [Internet]. [cited 2025 Apr 23]. Available from: https:\/\/medbud.wiki\/strains\/"},{"issue":"11","key":"355_CR64","doi-asserted-by":"publisher","first-page":"e15869","DOI":"10.2196\/15869","volume":"21","author":"E McCarthy","year":"2019","unstructured":"McCarthy E, Mazza D. Cost and effectiveness of using facebook advertising to recruit young women for research: PREFER (contraceptive preferences study) experience. J Med Internet Res. 2019;21(11):e15869.","journal-title":"J Med Internet Res"},{"issue":"8","key":"355_CR65","doi-asserted-by":"publisher","first-page":"e290","DOI":"10.2196\/jmir.7071","volume":"19","author":"C Whitaker","year":"2017","unstructured":"Whitaker C, Stevelink S, Fear N. The use of facebook in recruiting participants for health research purposes: a systematic review. J Med Internet Res. 2017;19(8):e290.","journal-title":"J Med Internet Res"},{"key":"355_CR66","unstructured":"Roy SS, Linden T. Evaluating the precision and bias\u00a0in AI-related facebook\u00a0advertising: a comprehensive analysis. Proceedings of the ISCAP Conference, Baltimore, v10 n6218;2024. ISSN:2473-4901."},{"key":"355_CR67","doi-asserted-by":"publisher","first-page":"204512532095499","DOI":"10.1177\/2045125320954992","volume":"10","author":"E Chesney","year":"2020","unstructured":"Chesney E, McGuire P, Freeman TP, Strang J, Englund A. Lack of evidence for the effectiveness or safety of over-the-counter Cannabidiol products. Therapeutic Adv Psychopharmacol. 2020;10:2045125320954992.","journal-title":"Therapeutic Adv Psychopharmacol"},{"key":"355_CR68","unstructured":"Government of the Netherlands. Toleration policy regarding soft drugs and coffee shops [Internet]. 2024 [cited 2024 Oct 14]. Available from: https:\/\/www.government.nl\/topics\/drugs\/toleration-policy-regarding-soft-drugs-and-coffee-shops"},{"key":"355_CR69","unstructured":"European Monitoring Centre for Drugs and Drug Addiction. Perspectives on drugs: Characteristics of frequent and high-risk cannabis users. 2013. Available from: https:\/\/www.euda.europa.eu\/publications\/pods\/frequent-cannabis-users_en"}],"container-title":["Journal of Cannabis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42238-025-00355-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42238-025-00355-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42238-025-00355-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T07:03:14Z","timestamp":1769756594000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s42238-025-00355-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["355"],"URL":"https:\/\/doi.org\/10.1186\/s42238-025-00355-y","relation":{},"ISSN":["2522-5782"],"issn-type":[{"value":"2522-5782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,2]]},"assertion":[{"value":"31 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was granted an exemption from ethics from the Medical-Ethical Review Committee METC NedMec (22\u2013912\/DB). The research was conducted in accordance with the Declaration of Helsinki. It also followed the Dutch code of conduct of scientific integrity (\u2018Nederlandse gedragscode wetenschappelijke integriteit\u2019). Participants provided informed consent before taking part in the survey.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6"}}